Glimy M V2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2 mg, Metformin 500 mg, and Voglibose 0.2 mg, formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, leading to a reduction in postprandial hyperglycemia. The sustained-release (SR) formulation ensures a gradual release of active ingredients, promoting better compliance and minimizing gastrointestinal side effects commonly associated with immediate-release formulations. Glimy M V2 is indicated as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on monotherapy or dual therapy. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. Potential adverse effects include hypoglycemia, gastrointestinal disturbances, and lactic acidosis, though the SR formulation may mitigate some gastrointestinal symptoms. This combination therapy offers a comprehensive approach by targeting multiple pathophysiological defects in type 2 diabetes.